The role of antioxidant therapy in patients with the new coronavirus infection of the Covid-19 of the Motenza and Severe

Authors:
E.K. SHAVAROVA^1,2, E.R. KAZAKHMEDOV¹, M.V. ALEXEEVA¹, L.G. EZHOVA², Zh.D. KOBALAVA¹

¹Peoples' Friendship University of Russia (RUDN University), Moscow, Russian Federation;
²Vinogradov City Clinical Hospital, Moscow Department of Health, Moscow, Russian Federation

Place of publication:
INFECTIOUS DISEASES, 2021, Vol. 19, No. 1, pp. 159–164

Abstract:
The novel coronavirus infection COVID-19 is characterized by high mortality and the lack of effective etiotropic therapy. Activation of oxidative stress may be one of the links in the pathogenesis of organ damage against the background of this infection. Objective. To evaluate the ability of Mexidol®^to influence the rate of clinical improvement in pneumonia in hospitalized patients with the novel coronavirus infection COVID-19. The study included 62 patients over 18 years of age with confirmed novel coronavirus infection COVID-19 based on computed tomography (CT) of the lungs (stages CT1, CT2, CT3) and polymerase chain reaction testing of nasopharyngeal and oropharyngeal swabs for SARS-CoV-2 viral RNA. After randomization, patients in group 1 received Mexidol infusion at a dose of 1000 mg/day for 7 days, patients in group 2 received an infusion of isotonic sodium chloride solution. Compared with the control group, patients treated with Mexidol demonstrated a significantly more pronounced decrease in body temperature and a trend toward a decrease in the severity of dyspnea. Superoxide dismutase concentrations remained virtually unchanged in the Mexidol group, while a downward trend was observed in the control group. C-reactive protein decreased 2.2 times more than in the control group (p = 0.09). Ferritin levels tended to decrease more rapidly in the active intervention group. Mexidol therapy may have a positive effect on the clinical manifestations and severity of laboratory-inflammatory syndrome in patients with COVID-19. Keywords: COVID-19, oxidative stress, Mexidol.